Letermovir 480 mg [PREVYMIS]
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Kidney Disease (ESKD)
Conditions
End-Stage Kidney Disease (ESKD)
Trial Timeline
Sep 1, 2025 → Dec 1, 2027
NCT ID
NCT07101055About Letermovir 480 mg [PREVYMIS]
Letermovir 480 mg [PREVYMIS] is a phase 1 stage product being developed by Merck for End-Stage Kidney Disease (ESKD). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07101055. Target conditions include End-Stage Kidney Disease (ESKD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07101055 | Phase 1 | Recruiting |
| NCT06066957 | Phase 2 | Recruiting |
Competing Products
20 competing products in End-Stage Kidney Disease (ESKD)